Mehmet Altan, MD
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2003 | Ankara University, School of Medicine, Ankara, TR, MD |
Postgraduate Training
| 2015-2017 | Clinical Instructor, Medical Oncology, Yale Cancer Center, Thoracic Oncology, New Haven, Connecticut |
| 2012-2015 | Clinical Fellowship, Hematology/Medical Oncology, Yale School of Medicine, New Haven, Connecticut |
| 2009-2012 | Clinical Residency, Internal Medicine, Hospital of St. Raphael, New Haven, Connecticut |
| 2004-2009 | Clinical Residency, Internal Medicine, Ankara University School of Medicine, Ankara |
Board Certifications
| 2015 | Medical Oncology, American Board of Internal Medicine |
| 2012 | Internal Medicine, American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Co-Chair, Department of Thoracic Service Line, Molecular Profiling Task Force, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Other Appointments/Responsibilities
Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Member, IASLC, Denver, CO, 2021 - 2023
Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Institutional Committee Activities
Member at Large, MD Anderson IO-Tox, 2023 - Present
Thoracic/Head and Neck Medical Oncology Faculty Representative, MD Anderson Cancer Center, Division of Cancer Medicine Wellness Committee, 2023 - Present
Member, MD Anderson Cancer Center, Credentials Committee of the Medical Staff (CCMS), 2021 - Present
Member, MD Anderson Cancer Center, Cancer Survivorship Research Advisory Workgroup, 2021 - 2024
Member, Thoracic/Head and Neck Medical Oncology, Screening and Correlatives Working Group, 2021 - Present
Co-Chair, Thoracic/Head and Neck Medical Oncology, Cellular Therapy Working Group, 2021 - 2023
Member, MD Anderson Cancer Center Network Peer to Peer Program, 2021 - Present
Member, Thoracic/Head and Neck Medical Oncology, Educational Committee, 2021 - Present
Member, Thoracic/Head and Neck Medical Oncology, Clinical Trial Activation Working Group, 2021 - Present
Member, Thoracic/Head and Neck Medical Oncology, Metastatic NSCLC Therapy Working Group (Front Line, Second Line and Beyond), 2021 - Present
Member, MD Anderson Cancer Center, IO-Tox Resources Subcommittee, 2021 - 2024
Co-Chair, MD Anderson Cancer Center IO-Tox Education Subcommittee, 2018 - 2024
MD Anderson Cancer Center, Scientific Reviewer, Scientific Review Committee 3 (Formerly Clinical Research Committee), 2017 - 2022
Senator, MD Anderson Cancer Center, Faculty Senate, 2017 - 2023
Member, Accreditation Council for Graduate Medical Education (ACGME) Medical Hematology and Oncology Fellow Representative, Yale University, 2013 - 2015
Member, Internal Medicine Resident Representative/Chief Medical Resident (CMR) Ankara University, 2007 - 2009
Honors & Awards
| Outstanding Resident in Patient Care, Hospital of St. Raphael Residency Program | |
| Outstanding Fellow in Research, Yale School of Medical Oncology and Hematology Fellowship Program | |
| Career ASCO Oncology Trainee Travel Award, ASCO | |
| 2017 LUNGevity Career Development Awardee, LUNGevity Foundation | |
| Rexanna Foundation Award | |
| IASLC (International Association for the Study of Lung Cancer) Academy, IASLC | |
| MD Anderson Top Performer, based on the Top 10% Nationally CAHPS Measures Related to Patient Care Experience Rating | |
| Faculty Academic Career Development Academy, The University of Texas MD Anderson Cancer Center | |
| Top 10% Nationally CAHPS Measure Related to Patient Care Experience Rating, The University of Texas MD Anderson Cancer Center |
Selected Publications
Peer-Reviewed Articles
- Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10):None, 2024. PMID: 39448200.
- Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun 15(1):3152, 2024. PMID: 38605064.
- Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol 14(None):1322818, 2023. PMID: 38152395.
- Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Lee X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and Ipilimumab with Concurrent Stereotactic Radiosurgery for Intracranial Metastases from Non-small Cell Lung Cancer: Analysis of the Safety Cohort for Non-randomized, Open-label, Phase I/II Trial. J Immunother Cancer 11(7), 2023. PMID: 37402581.
- Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist. e-Pub 2023. PMID: 37156009.
- Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A. Phase II Clinical Trial of Axitinib and Avelumab in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol 41(15):JCO2202221, 2023. e-Pub 2023. PMID: 36898078.
- Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing A. Safety, Tolerability, and Clinical Activity of Selinexor in Combination with Pembrolizumab in Treatment of Metastatic Non-small Cell Lung Cancer. Cancer. e-Pub 2023. PMID: 37129197.
- Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant Chemotherapy plus Nivolumab with or without Ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Platform NEOSTAR Trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
- Reid P, Sandigursky S, Song J, Lopez-Olivo MA, Safa H, Cytryn S, Efuni E, Buni M, Pavlick A, Krogsgaard M, Abu-Shawer O, Altan M, Weber JS, Rahma OE, Suarez-Almazor ME, Diab A, Abdel-Wahab N. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology 12(1):2261264, 2023. PMID: 38126033.
- Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final Efficacy Outcomes of Atezolizumab with Chemoradiation for Unresectable NSCLC: The Phase II DETERRED Trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
- Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults with Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer 23(3):S1525-7304, 2022. e-Pub 2022. PMID: 35216923.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients with HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results from a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2022. e-Pub 2021. PMID: 34550757.
- Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, Alessi JV, Vaz VR, Rizvi H, Egger J, Plodkowski AJ, Khosrowjerdi S, Digumarthy S, Park H, Vaz N, Nishino M, Sholl LM, Barbie D, Altan M, Heymach JV, Skoulidis F, Gainor JF, Hellmann MD, Awad MM. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Affected by KRAS Mutation Status. J Thorac Oncol 17(3):399-410, 2022. e-Pub 2021. PMID: 34740862.
- Keiser MF, Patel AB, Altan M. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy. Clin Lung Cancer 22(3):195-200.e1, 2021. e-Pub 2021. PMID: 33637416.
- Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
- Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Long-Term Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol 16(1):162-168, 2021. e-Pub 2020. PMID: 33069888.
- Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. e-Pub 2020. PMID: 32389639.
- Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab with Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2019. PMID: 31778797.
- Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. e-Pub 2019. PMID: 31605794.
- Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM. Safety of Programmed Death-1 Pathway Inhibitors Among Patients with Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol:JCO2017770305. e-Pub 2018. PMID: 29746230.
- Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20-selective Kinase Inhibitor in Non-small Cell Lung Cancer. Nat Med 24(5):638-646, 2018. e-Pub 2018. PMID: 29686424.
- Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Lius S, Li S, Chen T, Poteete A, Estrada Bernal A, At L, Triuni A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20-selective Kinase Inhibitor in Non-small Cell Lung Cancer. Nat Med 24:638-646, 2018. PMID: None.
- Altan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, Thomas DG, Sabel MS, Hayes DF, Rimm DL. Association of B7-H4, PD-L1, and Tumor Infiltrating Lymphocytes with Outcomes in Breast Cancer. NPJ Breast Cancer 4:40, 2018. e-Pub 2018. PMID: 30564631.
- Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clin Cancer Res 23(17):5202-5209, 2017. e-Pub 2017. PMID: 28539467.
- Altan M, Burtness B. EGFR-directed Antibodies Increase the Risk of Severe Infection in Cancer Patients. BMC Med 13:37, 2015. e-Pub 2015. PMID: 25857245.
Other Articles
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. PMID: 38965214.
- Altan M, Chiang AC Management of Small Cell Lung Cancer: Progress and Updates. Cancer J 21(5):425-33, 2015. PMID: 26389768.
Editorials
- Antonoff MB, Deboever N, Werner R, Altan M, Gomez D, Opitz I. Surgery for oligometastatic non-small cell lung cancer. J Thorac Cardiovasc Surg 167(2):508-516.e1, 2024. PMID: 37778504.
Selected Presentations & Talks
Local Presentations
- 2023. Roundtable Case Discussions: Integration of IOTOX and Oncologic Care, National IOTOX Clinical Education Symposium. None. Houston, Texas, US.
- 2023. Potential Combinations of Immunotherapy over the Next 5 years; Next Generation of Cancer Therapy Beyond Immunotherapy? Cancer Network Virtual Thoracic Retreat. None. Houston, Texas, US.
- 2023. Multidisciplinary Care Discussion Panel, Cancer Network Virtual Thoracic Retreat. None. Houston, Texas, US.
- 2023. Sheshadri A, Altan M. The Diagnostic Performance of Bronchoalveolar Lavage Lymphocytosis as a Predictive Marker of Immune Checkpoint Inhibitor Pneumonitis. None. FY23 IOTOX Research and Resources Meeting, IOTOX Working Group. Houston, Texas, US.
- 2023. Personalized Therapy for Lung Cancer, 14th Interventional Pulmonology in Cancer Patients. None. Houston, Texas, US.
- 2022. Management of Common and Challenging Immune-Related Adverse Events, Advances in Cancer Immunotherapy: A Focus on Toxicity Management, Society for Immunotherapy of Cancer (SITC). None. Houston, Texas, US.
- 2021. Incidence and Risk Factors for Pneumonitis Associated with Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience, Immunotoxicities Retreat. None. Houston, Texas, US.
- 2021. Immunotherapy Related Toxicities, MD Anderson Cancer Center Onco-Hospital Medicine Conference. None. Houston, Texas, US.
- 2021. Therapies in Metastatic Lung, Annual Multidisciplinary Cancer Care Conference. None. Houston, Texas, US.
- 2021. Management of Immune-Related Adverse Effects, 8th Lung Cancer Network Virtual Symposium: Bridging Science and Practice. None. Houston, Texas, US.
- 2020. Clinical Trials and Advances, The University of Texas MD Anderson Cancer Center and Physicians Network Multidisciplinary Planning Conferences (MPC). None. Houston, Texas, US.
- 2020. Pneumonitis with Immunotherapy in Non-Small Cell Lung Cancer: Navigating Scylla and Charybdis, Division of Cancer Medicine Grand Rounds. None. Houston, Texas, US.
- 2019. Immunotherapy and Management of Head and Neck Cancers: Updates, Medical Oncology and Hematology 2019: Multidisciplinary Approaches that Improve Coordination of Care. None. Houston, Texas, US.
- 2018. Multidisciplinary Lung Cancer Tumor Board, The Cancer Imaging and Intervention Conference. None. Houston, Texas, US.
- 2018. Immunotherapy Toxicities in Head and Neck Cancers: Updates in Cancer Immunotherapy and Toxicity Management. None. Houston, Texas, US.
- 2018. Immunotherapy and Management of Head and Neck Cancers: Update, Multidisciplinary Approaches that Improve Coordination of Care Meeting. None. Houston, Texas, US.
National Presentations
- 2023. Impact of Frailty and Other Co-Morbidities on Lung Cancer Outcomes. Invited. ASTRO 2023 Multidisciplinary Thoracic Cancers Symposium. New Orleans, Louisiana, US.
- 2023. Neoadjuvant Therapy in Non-Small Cell Lung Cancer, National Lung Cancer Congress. Invited. (AKAD) Lung Cancer Research Foundation. Antalya, TR.
- 2021. NKTR-255 Plus Cetuximab in Patients with Solid Tumors: Interim Safety and Efficacy Results from the Phase 1b Dose Escalation Study, Poster Presentation, Late Breaking Abstract. Invited. Society for Immunotherapy of Cancer (SITC), 37th Annual Meeting, Virtual Meeting, US.
- 2021. Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons D, Vaporciyan A, Heymach JV, Mott FE, Altan M. Clinical Outcomes of Immunotherapy Continued Beyond Radiographic Progression in Older Adults with Advanced Non-Small Cell Lung Cancer. Invited. Washington, DC, US.
- 2021. Barnes B, Shan M, Blouch K, Altan M, Kim J, Ramos-Hernandez N, Corigliano E. Analysis of NY-ESO-1 Expression in Specimens from a Phase I/II NY-ESO-1 T-cell Therapy Clinical Trial in Non-small Cell Lung Cancer and from Exploratory Studies in Multiple Tumor Type. Invited. Washington, DC, US.
- 2021. Immune Related Adverse Events and Management of these Toxicities in Cancer Therapy, International Oncological Emergency Congress. Invited. Turkish Association of Lung Cancer (TAKD), US.
- 2021. Schoenfeld AJ, Altan M, Owonikoko TK, D'Angelo S, Ladle BH, Noujaim H, He K, Liebner D, Sacher AG, Haanen JB, Yachnin J, Huang C, Van Tine BA, Hasan A, Faitg T, Butler E, Shalabi A, Attia S, Araujo DM. Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generation NY-ESO-1-specific TCR T-cells in HLA-A*02 Patients with Synovial Sarcoma and Non-small Cell Lung Cancer. Invited, US.
- 2020. Li J, Wang Y, Tang C, Welsh JW, Guha- Thakurta N, Carter BW, Wefel JS, Ghia AJ, Yeboa D, McAleer MF, Chung C, Woodhouse KD, Elamin Y, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach J, Altan M. Concurrent Nivolumab and Ipilimumab with Brain Stereotactic Radiosurgery for Brain Metastases from Non-small Cell Lung Cancer: A Phase I Trial. Invited, US.
- 2018. Immunotherapy Toxicities and Management Updates. Invited. IASLC 6th Annual Lung Cancer Network Symposium. Istanbul, TR.
- 2016. Quantitative Measurement of B7-H3 and B7-H4 Protein Expression and their Correlation with PD-L1 in Non-small Cell Lung Cancer. Invited. IASLC 16th Annual Targeted Therapies of Lung Cancer Meeting. Santa Monica, California, US.
- 2015. Altan M, Schalper K, Silver M, Rimm DL. Expression and Significance of the Co-regulatory Ligands B7-H4 and PD-L1 in Triple Negative Breast Cancer. Invited. Chicago, Illinois, US.
- 2015. Association between the Levels of the Tumor Differentiation Marker TTF-1 and PD-L1 Protein in Non-small Cell Lung Cancer. Invited. IASLC 15th Annual Targeted Therapies of Lung Cancer Meeting. Santa Monica, California, US.
International Presentations
- 2024. First-line Systemic Therapies in Advance NSCLC without Actionable Mutations in the Immunotherapy Era. Invited. Precision Oncology Saudi Summit (POSS2024). Al-Mandinah Al-Munawaroh, SA.
- 2021. Altan M, Patnaik A, Barve MA, Dunn L, Cobb PW, Rosenberg A, Sharma S, Sukari A, Lee Z, Marcondes MQ, Zalevsky J, Tagliaferri MA, Kotzin B, Sacco AG. A Phase IB/II, Open-label, Multicenter, Dose-escalation and Dose-expansion Study of NKTR-255 plus Cetuximab as a Salvage Regimen in Patients with Solid Tumors. Invited, US.
- 2021. Altan M, Govindan R, Schoenfeld AJ, Noujaim J, Sacher AG, Haanen JB, Huang C, Hasan A, Faitg T, Butler E, Shalabi A, Owonikoko TK. CD8α-Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) In HLA-A*02 Patients With NSCLC: Master Protocol Substudy 1. Invited, US.
- 2021. Altan M, Govindan R, Schoenfeld A, Noujaim J, Sacher AG, Haanen J.B.A.G, Huang C, Hasan A, Faitg T, Butler E, Shalabi A, Owonikoko TK. CD8α-Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1. Invited, US.
- 2017. Altan M, Fossella F, Zhang J, Landry LCA, Roarty EB, Roth J, Swisher S, Heymach JV. Single Institutional Experience of the Use of PD-1/PD-L1 Inhibitors among Patients with Non-small Cell Lung Cancer and Preexisting Autoimmune Diseases. Invited. Tokyo, JP.
- 2015. Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Syrigos KN, Herbst RS, Rimm DL. Significance of PD-L1, IDO-1 and B7-H4 Expression in Lung Cancer. Invited. Chicago, US.
- 2010. Altan M, Fiedler P, Shaib W. Hypercalcemia Related to Acute T-Cell Lymphoma: An Unknown Mechanism. Invited, US.
- 2010. Toruner M, Altan M, Savas B, Soykan I, Cetinkaya H, Ensar A. The Effect of Vitamin D on an Animal Model of Inflammatory Bowel Disease Related Colon Cancer. Invited. Prague, CZ.
- 2003. Buyrukcu B, Altan M, Sav H, Gullu S. Comparison of Thyroid Palpation and Ultrasonographic Findings. Invited. Bahreyn, BH.
- 2003. Akan OA, Altan M, Yuksel MK, Arat M, Uysal S, Akan H. Intravascular Catheter Infections among Hematology Patients at Ankara University Hospital,. Invited. Istanbul, TR.
Grant & Contract Support
| Title: | A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma or Mesothelioma |
| Funding Source: | Verismo Therapeutics |
| Role: | PI |
| Title: | CIAG933A12101 An open-label, multi-center, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors 2021-0750 |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platin |
| Funding Source: | GSK Pharma |
| Role: | PI |
| Title: | A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel alone in participants with Advanced Non-Small Cell Lung Cancer who have progressed on prior Anti-PD-(L)1 Therapy and Chemotherapy |
| Funding Source: | GlaxoSmithKlien |
| Role: | PI |
| Title: | LYL797, RORI-Targeting CAR T Cells in Adults with Relapsed and/or Refractory Solid tumor Malignancies |
| Funding Source: | Lyell Immunopharma, Inc |
| Role: | PI |
| Title: | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers |
| Funding Source: | Xencor |
| Role: | PI |
| Title: | Targeting EGFR neoantigens by combining peptide vaccination with Osimertinib for treatment of NSCLC |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Clinical and radiomic tools linking interstitial lung disease risk markers to immune checkpoint inhibitor pneumonitis |
| Funding Source: | NIH |
| Role: | Co-I |
| Title: | Phase I/II trial of Nivolumab with Radiation or Nivolumab and Ipilimumab with Radiation for the Treatment of Intracranial Metastases from Non-small Cell Lung Cancer |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Co-PI |
| Title: | A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma, 2013-0984 |
| Funding Source: | Merck |
| Role: | PI |
| Title: | A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma |
| Funding Source: | Gilead Sciences Inc |
| Role: | PI |
| Title: | A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel alone in participants with Advanced NSCLC who have progressed on prior Anti-PD-(L)1 Therapy and Chemo (COSTAR LUNG) |
| Funding Source: | GlaxoSmithKline |
| Role: | CO-I |
| Title: | Tumor Volumetric Measurements to Improve Immune Checkpoint Inhibitor Responses Assessment and Prediction |
| Funding Source: | Rexanna Foundation Award |
| Role: | PI |
| Title: | Prediction of Pneumonitis after Sequential Chemoradiation and Immunotherapy in Non-small Cell Lung Cancer Patients |
| Funding Source: | Gateway |
| Role: | PI |
| Title: | Strategic Collaboration Agreement - NKTR-255 |
| Funding Source: | Nektar Therapeutics |
| Role: | CO-I |
| Title: | A Randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | An Open-label, Multi-center, Phase I Study of OralIAG933 in Adult Patients with Advanced Mesothelioma and other Solid Tumors |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPa-Fc-CD40L), Administered Intratumorally in Subjects with Cutaneous Squamous Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck |
| Funding Source: | Shattuck Labs |
| Role: | PI |
| Title: | Study of NKTR 255 in Combination with Cetuximab in Solid Tumors, 2020-1122 |
| Funding Source: | Nektar therapeutics |
| Role: | PI |
| Title: | Texas Experimental Cancer Therapeutics Network - TEX CTN |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| Title: | A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors |
| Funding Source: | Nektar Therapeutics |
| Role: | PI |
| Title: | Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-small Cell Lung Cancer or Bladder Cancer (EMERGE) SIV |
| Funding Source: | Jounce Therapeutics |
| Role: | PI |
| Title: | A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination with Docetaxel versus Placebo in Combination with Docetaxel in Subjects with Non-small Cell Lung Cancer (NSCLC) Previously Treated with PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY-2) |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | Innate Immune Phagocytic Checkpoint CD47 Blockade for Treating HPV-positive Oropharyngeal Cancers |
| Funding Source: | Steifel Oropharynx Program- Clinical Trials Award |
| Role: | PI |
| Title: | A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) |
| Funding Source: | GlaxoSmithKline |
| Role: | PI |
| Title: | A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies, 2018-0833, (Assumed PI Responsibility on 8/28/2018) |
| Funding Source: | Nektar Therapeutics |
| Role: | PI |
| Title: | Identification of Predictive Markers of Toxicity to Immunotherapy |
| Funding Source: | LUNGevity Foundation, Career Development Grant |
| Role: | PI |
| Title: | Genomic Markers for Toxicity to Immunotherapy in Metastatic Lung Cancer |
| Funding Source: | Rexanna Foundation Award |
| Role: | PI |
| Title: | A Study of a CD122-Biased Cytokine (NKTR-214) in Combination with Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors |
| Funding Source: | PROPEL |
| Role: | PI |
| Title: | Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC), (Assumed PI responsibility on 05/28/2019) |
| Funding Source: | Adaptimmune |
| Role: | PI |
| Title: | ANCHoR- Advanced Non-Small Cell Lung Cancer Holistic Registry: PD-L1 Testing Patterns, PD-1/PD-L1 Inhibitor Utilization and Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer at an Academic Medical Center |
| Funding Source: | Merck |
| Role: | PI |
| Title: | A Phase Ib Trial of LY2606368 in Combination with Chemoradiation in Patients with Locally Advanced Head and Neck Squamous Cell Cancer, (Assumed responsibility on 09/01/2017) |
| Funding Source: | Eli Lily |
| Role: | PI |
| Title: | A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Carboplatin + NAB-Paclitaxel for Chemotherapy -Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer, (Assumed PI responsibility on 08/28/2018) |
| Funding Source: | Genentech Inc |
| Role: | PI |
| Title: | A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer, 2013-0691 |
| Funding Source: | Merck |
| Role: | PI |
Patient Reviews
CV information above last modified February 03, 2025